Cd133+ Cell Infusion in Patients With Colorectal Liver Metastases.

Colorectal Cancer Clinical Trial

— cellcol  

Official title:

Cd133+ Cell Infusion in Patients With Colorectal Liver Metastases That Are Going to be Submitted to a Major Liver Resection

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03803241
• Other study ID #: 2014-001402-18
• Status: Completed
• Phase: Phase 2
• Start date: May 31, 2019
• Est. completion date: June 30, 2021

Study information

• Verified date: September 2021
• Source: Hospital San Carlos, Madrid
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Treatment of patients with metastatic colorectal carcinoma is surgical resection. Only 10-15% of the patients will be candidates for curative resection. After response to chemotherapy this figure rises 10-13% more. To perform the surgery it is necessary to have a sufficient remnant liver volume (RLV), which allows maintaining optimal liver function after resection. If the estimated RLV is insufficient preoperatively, portal venous embolization site (PVE) is performed for compensatory hypertrophy, thus increasing the number of resections 19%. Still, in 20% of these patients surgery can not be performed because RLV is not achieved or because the disease progresses while waiting for growth. Therefore, it is necessary to improve liver regeneration without promoting tumor growth. Studies on liver regeneration, have determined that cells (CD133 +) are involved in the liver hypertrophy that occurs after hepatectomy. CD133 + have been used to induce liver hypertrophy with encouraging results. This population of CD133 +, can be selected from peripheral blood after stimulation with Granulocyte colony-stimulating factor (G-CSF), being able to obtain a large number of them. The investigators propose to treat patients who do not meet criteria for surgery because of insufficient volume <40%, with CD133 + and portal embolization in order to carry out a surgical resection in a second place.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 4
• Est. completion date: June 30, 2021
• Est. primary completion date: December 31, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion criteria:

1. Men and women between = 18 years and = 80. Women in fertile age should use contraceptive methods recommended by the Clinical Trial Facilitation Group (CTFG).

2. ECOG (Eastern Cooperative Oncology Group) quality of life scale = 2.

3. Patients with hepatic metastases of colorectal carcinoma and insufficient hepatic remnant function to perform a major hepatectomy. This volume would be calculated by Positron emission tomography-Computed tomography (PET-CT) images or 64-channel multidetector CT. In patients who have received preoperative chemotherapy, the estimate residual liver volume to be included in the study will be <40%. Patients who have preserved liver function (Child = B7 and International Normalized Ratio (INR) = 2 in non-anticoagulated patients) and those who have not received chemotherapy, needs < 30% of residual volume to be included in the study.

4. Patients should have signed informed consent.

Exclusion criteria:

1. Pregnancy or lactation period.

2. Any condition that the investigators consider an unjustifiable risk in the patient.

3. Severe comorbidities: American Society of Anesthesiologists (ASA) = 4.

4. Alterations in the hemogram and morphological alterations, evaluated by hematologist prior to administration of G-CSF.

5. Liver function: Child = B7 and INR = 2 in non-anticoagulated patients. In anticoagulated patients the values will have to be reverse, prior to surgery.

6. Patients who have not received research drugs in the last 30 days or in the period of 5 elimination half-life.

7. In patients on chemotherapy treatment, G-CSF can not be administered until 48 hours after the last administration of chemotherapy. Patients who have received Bevacizumab must wait 30 days since the last administration.

8. In addition, all those aspects that prevent the patient from being part of the study, understand the rules, follow the instructions given, or other aspects.

Related Conditions & MeSH terms

• Colorectal Cancer
• Colorectal Neoplasms

Intervention

Drug:
• CD133+ infusion
Infusion of cells cd133+

Other:
• portal vein embolization
portal vein embolization

Locations

Country	Name	City	State
Spain	Alejandra Garcia Botella	Madrid
Spain	Hospital Clinico San Carlos	Madrid

Sponsors (1)

Lead Sponsor	Collaborator
Hospital San Carlos, Madrid

Country where clinical trial is conducted

Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Liver volume	Liver volume estimated by computed tomography	once residual liver volume reach >40%, an average of 5 weeks.
Secondary	Liver volume	Liver volume estimated by computed tomography	Post-surgery follow-up visits the first 30 days
Secondary	Liver volume	Liver volume estimated by computed tomography	Post-surgery follow-up visits the first 90 days
Secondary	Liver volume	Liver volume estimated by computed tomography	Post-surgery follow-up visits the first 180 days
Secondary	Liver volume	Liver volume estimated by computed tomography	Post-surgery follow-up visits the first 12 months
Secondary	Liver volume	Liver volume estimated by computed tomography	Post-surgery follow-up visits the first 18 months
Secondary	Liver volume	Liver volume estimated by computed tomography	Post-surgery follow-up visits the first 24 months